Prime Capital Investment Advisors LLC Reduces Stock Holdings in Boston Scientific Corporation $BSX

Prime Capital Investment Advisors LLC cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 14.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,966 shares of the medical equipment provider’s stock after selling 1,885 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Boston Scientific were worth $1,178,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BSX. Vanguard Group Inc. grew its position in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Boston Scientific by 5.3% in the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock worth $1,677,124,000 after buying an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after buying an additional 1,383,524 shares during the period. Amundi grew its holdings in shares of Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock valued at $1,212,408,000 after buying an additional 311,034 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Boston Scientific by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock valued at $1,139,938,000 after acquiring an additional 460,580 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on BSX shares. Evercore ISI lowered their price target on Boston Scientific from $115.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday. Wells Fargo & Company raised their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Robert W. Baird increased their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $120.71.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $96.73 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock has a market capitalization of $143.33 billion, a price-to-earnings ratio of 57.58, a PEG ratio of 2.31 and a beta of 0.61. The firm’s 50 day simple moving average is $102.34 and its 200-day simple moving average is $101.96. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s revenue was up 22.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.